Insider Trading Watch List: Mallinckrodt PLC $MNK

4c2fb3f2654bee77bbec35b233aa3b00

Mallinckrodt PLC (NYSE:MNK) insider have most recently took part in a trading activity. On Nov 28, 2017 Youngblood Dr Kneeland, Director bought 4,560 shares having total worth of $100,046 at the price of $21.94 per share, following the transaction a total of 19,789 shares owned by Youngblood Dr Kneeland.

The stock has experienced a total of 12 insider trades in the past three months. These trades include 12 buy trades. Furthermore, over the past 12 months , the stock was traded 27 times by insiders. an employee of the company was the buyer in 27 instances.

Time Frame Number of Insider Buy Number of Insider Sell Stock Price Change(%)
3 Month 12 0 -53.33%
12 Month 27 0 -60.85%

Shares of Mallinckrodt PLC (NYSE:MNK) traded up 0.96% on Nov 29, 2017, hitting $22.13. 4,241,992 shares of the company’s stock traded hands. Mallinckrodt PLC has a 52 week low of $19.98 and a 52 week high of $83.06. The company’s market cap is $7,670 million.

Mallinckrodt PLC (NYSE:MNK) last announced its earnings results on Nov 7, 2017. The company reported 1.97 earnings per share (EPS) for the quarter, higher than the consensus estimate of 1.81 by $0.16. The company had revenue of $794 million for the quarter, compared to the consensus estimate of $812 million. During the same quarter in the previous year, the company posted 2.04 earnings per share. The company’s revenue for the quarter was down 11% on a year-over-year basis.

2017-11-07 2017-08-08 2017-05-08 2017-02-07 2016-11-29 2016-08-02 2016-05-03 2016-02-02 2015-11-23 2015-08-04
earnings per share 1.97 1.85 1.68 1.91 2.04 2.20 2.01 2.09 1.84 2.05
Revenue(M) 793.9 824.5 810.9 829.9 887.2 970.6 918 914.8 882.4 965.1

Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company’s Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company’s products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company’s nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems’ products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.